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preferences questionnaire was elaborated in a pilot study: treat-
ment mode of administration, time spent in hospital for admin-
istration, immediate toxicity, and level of symptoms control;
distributed in 9 hypothetic scenarios. Second line NSCLC
patients were asked to score by preferred scenario, through the
conjoint analysis method. Socio-demographic, clinical and
health-related quality of life (RSCL) characteristics were col-
lected and linear regression models were performed. RESULTS:
A total of 172 patients were enrolled. Mean (SD) age 61.9 (10.5)
years. Seventy-ﬁve percent were men, 84.8% in NSCLC stage IV,
50% ECOG 1 20.3% of patients received cisplatine +
gemcitabine in ﬁrst line, 30.8% showed treatment’s adverse reac-
tions and 52.9% were scheduled to erlotinib as second line.
Psychological symptoms’ was the most affected RSCL dimension.
The ICC of questionnaire’s scenarios was assessed (0.55–
0.88).The most preferred attribute was symptoms’ control and
the most preferred scenario was: oral administration, no time
spent in hospital, low toxicity and total symptoms’ control (G
scenario). Patients who started oral administration vs patients
who started intravenous administration, gave more utility/
importance to the attributes ‘treatment administration’ (0.30 vs
-0.12) and ‘time spent in hospital’ (0.62 vs 0.45). Psychological
and daily functioning affection, ECOG 1-2 and adverse reactions
in ﬁrst line were related to G scenario. CONCLUSIONS: The
most valued attributes by advanced NSCLC patients are
moderate-total symptoms’ control and oral administration.
Patients with worst functional status and psychological affection
preferred total symptoms’ control, oral administration, no time
spent in hospital and low toxicity. Treatment preference’s ques-
tionnaire showed utility, feasibility and reliability for treatment
decisions, allowing physicians to explore patients’ preferences
before initiating treatment.
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OBJECTIVES: To evaluate whether shared decision making
in treatment selection for cancer differs by race. METHODS:
Newly diagnosed local stage prostate cancer patients and their
family members were recruited following biopsy but prior to
initiating treatment at urology practices in three states to partici-
pate in a take-home survey. RESULTS: A total of 192 family
pairs completed surveys. In 14% of the family pairs, at least one
subject was black, 13% had a Hispanic member, and 66% had
no minority members. Discussions between patients and family
members about treatment options occurred “very” often among
26% of black families, 30% of Hispanic families, 52% of white
families (p = 0.06). Patients reported differences by race in how
extensively physicians involved them (60% among blacks, 79%
among Hispanics, and 49% among whites, p = 0.04). 91% of
family members reported attending physician visits with the
patient; 66% indicated their role was to help the patient make a
treatment choice, 72% reported the physician involved them in
the decision process, and 61% reported “excellent” satisfaction
with the patient’s doctor with no signiﬁcant differences by race.
In multivariate analyses, family members who perceived that the
patient’s physician did not involve them were signiﬁcantly less
likely to be highly satisﬁed (OR = 0.22, 95% CI 0.10–0.48).
CONCLUSIONS: Family members of all races often attended
clinic visits and discussed treatment options with physicians.
Compared to whites, black and Hispanic patients, but not family
members, reported more encouragement by physicians to be
involved in the decision process. Black and Hispanic families
were less likely to discuss treatment options among themselves.
Family member satisfaction was dependent on their perception of
whether the physician involved them in the decision process.
Race may be less of a factor when physicians involve patients and
family members extensively in the treatment decision making
process.
PCN90
DEVELOPMENT OF AN EFFECTIVE HOME PALLIATIVE CARE
SYSTEM ADOPTING A MULTIDISCIPLINARYTEAM
APPROACH—SATISFACTION OFTHE PATIENTS’ FAMILY FOR
THE DOMICILIARY PALLIATIVE CARE “OKAYAMA” MODEL
Saito S1, Shimozuma K2,Yamaguchi M3
1Kochi Women’s University, Kochi, Japan, 2Ritsumeikan University,
Kusatsu, Shiga, Japan, 3Japanese Red Cross Hiroshima College of
Nursing, Hatsukaichi, Japan
OBJECTIVES: “Domiciliary palliative care ‘OKAYAMA’ model”
in which specialist palliative care team cooperates with primary
care team, is attracting attention to promote a home palliative
care service in Japan. To evaluate the outcome of this
“OKAYAMA model”, we investigated the satisfaction of the
patients’ family who received the home palliative care service by
this model. METHODS: A survey form consisting of 20 items
from the FAMCARE Scale was then sent to 83 surviving family
members of patients who had received care under this
“OKAYAMA” palliative care model. The study plan was
reviewed and approved by an ethics committee. RESULTS: The
mean score for the survey was 3.94  0.19 points (out of a
possible 5). Responses of “satisﬁed” or better were received by
more than 50% of respondents for nearly all items. The ratings
were high for “pain relief,” “answers from health professionals,”
“availability of doctors to the family,” “doctor’s attention to the
patient’s description of symptoms,” and “availability of the
doctor to the patient.” A positive assessment was made for time
spent and efforts made to respond to the desires of patients’
families following the conclusion of pain control prior to home
palliative care. Conversely, issues remain in items such as “avail-
ability of a hospital bed.” Four factors were identiﬁed in a factor
analysis of the FAMCARE Scale: “adequate amount of informa-
tion,” “attitude of medical personnel,” “education and support
system for families,” and “emergency responses.” Only 44% of
respondents were satisﬁed with the care provided by the respon-
dents themselves as a family member, suggesting the need for
environmental improvements to ease the burden on families.
CONCLUSIONS: The results of this study help us to develop an
appropriate model for a home palliative care system using a
multidisciplinary team approach.
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OBJECTIVES: To elicit treatment preference and WTP for Meth-
ylnaltrexone, a novel peripheral opioid antagonist versus existing
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therapies for managing palliative care patients with Opioid
Induced Constipation (OIC). METHODS: The study was con-
ducted by developing and administering a survey composed of a
modiﬁed decision board and a WTP instrument to subjects
recruited from the general public in Ontario, Canada (N = 401).
The decision board described the state of OIC, therapeutic
options and the outcomes and side effects associated with each
option. Participants stated their therapeutic preference and those
who preferred methylnaltrexone were subsequently presented
with a WTP instrument which elicited the hypothetical amount
of money they would be willing to pay out-of-pocket per week
and as additional monthly insurance premium for the therapeutic
option that included methylnaltrexone. Kruskal-Wallis test, Wil-
coxon Rank-Sum test, chi-square tests and multiple linear regres-
sion analysis were performed to assess the inﬂuence of
demographics and other variables on treatment preference and
WTP. RESULTS: Majority of the participants (N = 241) chose
the methylnaltrexone plus laxative regimen as their therapeutic
preference (60% vs. 36%, 4% indifferent). Treatment prefer-
ences were found to be signiﬁcantly different between age groups
(p < 0.001) and education levels (p = 0.021). The mean WTP for
out-of-pocket expenses per week was $163.42 with values
ranging from $0 to $ 2308. The overall mean additional monthly
premium was $8.65. Household income was a signiﬁcant predic-
tor of out of pocket amount (p < 0.05). Other demographic
parameters did not have a signiﬁcant impact on WTP. CONCLU-
SIONS: In this study population, which determined the
maximum WTP for treatment of OIC, most participants were
willing to pay to have methylnaltrexone added to conventional
therapies. The WTP values need to be further incorporated in a
formal cost beneﬁt analysis.
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OBJECTIVES: quality of life (QOL) is an important outcome in
lung patient (LC) treated by chemotherapy. Alopecia may be an
important part of this QOL but in fact very few data’s are
availablethe aim of this study is to assess, in patients treated by
chemotherapy, the impact of alopecia. METHODS: This pro-
spective, single centre study, use a willingness to pay method.
Advanced LC patients were asked ﬁrst to assess the impact of
alopecia in second line chemotherapy setting from an analogical
visual scale (from 0: no impact to 10 major impact); then they
participated, in a face to face interview, at the presentation of a
hypothetical scenario giving the choice between 2 chemothera-
pies with the same efﬁcacy, the same pattern of administration
(every 3 weeks, in day care hospital) and the same tolerability
except for the risk of alopecia : 5% for the product A and 40%
for the product B and were asked for their willingness to pay for
product A. RESULTS: Sixty-four patients had been enrolled
(59%, age : 60,8  10,3 y, married 58%). In analogical visual
scale, the impact of alopecia were assessed at 4,1  3,4. Patients
were willing to pay, for a 3-week chemotherapy cycle, a median
amount of €130,4  151.9 (median 62.5) to receive the product
with the lower rate of alopecia. But 27 (42.2%) are not ready to
pay anything. The patients no willing to pay are more often men
(p < 0.001), no married (p < 0,03), have low income (p < 0,001)
and hairless before treatment (p < 0.001). Correlation between
the results of the analogical visual scale and the willingness to
pay is good. CONCLUSIONS: a limit of this study is the context
of the French health system (universal health coverage) with no
payment by the patient for chemotherapy treatment than the
scenario tested is really hypothetical and may under or over
estimated the real willingness to pay of the participants. Prospec-
tive international studies are needed to conﬁrm these preliminar-
ies results.
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OBJECTIVES:To assess the impact of a cost attribute on prefer-
ences for a surgical treatment, in particular Surgical Excision (SE)
and Mohs Micrographic Surgery (MMS), to remove primary
Basal Cell Carcinoma (BCC). METHODS: Six attributes (recur-
rence, re-excision, travel time, surgical time, waiting time surgi-
cal results, costs) and their levels were selected, based on results
of a clinical trial, a cost-effectiveness study, a review and a focus
group of patients who recently had received treatment for BCC.
Two DCEs, one without (DCE_nocost) and one with a cost
attribute (DCE_cost) were conducted among the general public.
Outcomes of both DCEs were compared in terms of theoretical
validity, relative importance of the attributes and the rank order
of preferences. RESULTS: Except for travel time in DCE_nocost,
respondents in both DCEs valued a surgical treatment with a
lower level for all the selected attributes. Differences in ordering
of attribute importance occurred with the attribute waiting time
surgical results which was third in DCE_nocost and ended as last
in DCE_cost. The incremental utility score for DCE_nocost was
1.497 while the incremental willingness to pay for DCE_cost
amounted to € 847 in DCE_cost, both indicating a preference of
MMS to SE. CONCLUSIONS: From a policy perspective, results
show that the inclusion of a cost-variable does not change the
rank order of preferences for a surgical treatment to remove
BCC. However, the results of our comparison are speciﬁc to the
clinical setting of primary BCC and the surgical procedures MMS
and SE. Further research within different settings will be needed
to conﬁrm our ﬁndings.
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OBJECTIVES: About one in every eight women in The Nether-
lands develops breast cancer. Every year, 11,000 new cases are
registered and about 3500 women die of breast cancer. Prognosis
after primary treatment for patients with breast cancer is improv-
ing. This leads to an increased number of patients in follow-up,
which leads to increased workload. One of the main goals of
follow-up is to improve the survival of patients. This study aims
to determine a more individualized follow-up by modelling cost-
effectiveness of various follow-up scenarios and by determining
individual preferences by using a discrete choice experiment
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